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BACKGROUND
Central sleep apnea is associated with poor prognosis and death in patients with 
heart failure. Adaptive servo-ventilation is a therapy that uses a noninvasive venti-
lator to treat central sleep apnea by delivering servo-controlled inspiratory pressure 
support on top of expiratory positive airway pressure. We investigated the effects 
of adaptive servo-ventilation in patients who had heart failure with reduced ejec-
tion fraction and predominantly central sleep apnea.
METHODS
We randomly assigned 1325 patients with a left ventricular ejection fraction of 45% 
or less, an apnea–hypopnea index (AHI) of 15 or more events (occurrences of ap-
nea or hypopnea) per hour, and a predominance of central events to receive 
guideline-based medical treatment with adaptive servo-ventilation or guideline-
based medical treatment alone (control). The primary end point in the time-to-
event analysis was the first event of death from any cause, lifesaving cardiovascu-
lar intervention (cardiac transplantation, implantation of a ventricular assist 
device, resuscitation after sudden cardiac arrest, or appropriate lifesaving shock), 
or unplanned hospitalization for worsening heart failure.
RESULTS
In the adaptive servo-ventilation group, the mean AHI at 12 months was 6.6 events 
per hour. The incidence of the primary end point did not differ significantly be-
tween the adaptive servo-ventilation group and the control group (54.1% and 
50.8%, respectively; hazard ratio, 1.13; 95% confidence interval [CI], 0.97 to 1.31; 
P = 0.10). All-cause mortality and cardiovascular mortality were significantly 
higher in the adaptive servo-ventilation group than in the control group (hazard 
ratio for death from any cause, 1.28; 95% CI, 1.06 to 1.55; P = 0.01; and hazard 
ratio for cardiovascular death, 1.34; 95% CI, 1.09 to 1.65; P = 0.006).
CONCLUSIONS
Adaptive servo-ventilation had no significant effect on the primary end point in 
patients who had heart failure with reduced ejection fraction and predominantly 
central sleep apnea, but all-cause and cardiovascular mortality were both increased 
with this therapy. (Funded by ResMed and others; SERVE-HF ClinicalTrials.gov 
number, NCT00733343.)
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Sleep-disordered breathing is com-mon in patients who have heart failure with reduced ejection fraction, with re-
ported prevalence rates of 50 to 75%.1 Obstruc-
tive sleep apnea occurs more often in patients 
with heart failure than in the general popula-
tion. Central sleep apnea, which may manifest 
as Cheyne–Stokes respiration, is found in 25 to 
40% of patients who have heart failure with re-
duced ejection fraction.2 The prevalence of cen-
tral sleep apnea increases in parallel with in-
creasing severity of heart failure1 and worsening 
cardiac dysfunction.3
There are a number of mechanisms by which 
central sleep apnea may be detrimental to car-
diac function, including increased sympathetic 
nervous system activity and intermittent hypox-
emia.4-6 Central sleep apnea is an independent 
risk marker for poor prognosis and death in 
patients with heart failure.4,7,8
In the Canadian Continuous Positive Airway 
Pressure for Patients with Central Sleep Apnea 
and Heart Failure (CANPAP) study, patients with 
heart failure and central sleep apnea were ran-
domly assigned to receive continuous positive 
airway pressure (CPAP) or no CPAP.9 The trial 
was stopped prematurely and did not show a 
beneficial effect of CPAP on morbidity or mor-
tality. A post hoc analysis suggested that mortal-
ity might be lower if the apnea–hypopnea index 
(AHI; the number of occurrences of apnea or 
hypopnea per hour of sleep) is reduced to less 
than 15 events per hour.10
Adaptive servo-ventilation is a noninvasive ven-
tilatory therapy that effectively alleviates central 
sleep apnea by delivering servo-controlled inspi-
ratory pressure support on top of expiratory 
positive airway pressure.11,12 The Treatment of 
Sleep-Disordered Breathing with Predominant 
Central Sleep Apnea by Adaptive Servo Ventilation 
in Patients with Heart Failure (SERVE-HF) trial 
investigated the effects of adding adaptive servo-
ventilation (AutoSet CS, ResMed) to guideline-
based medical treatment on survival and cardio-
vascular outcomes in patients who had heart 
failure with reduced ejection fraction and pre-
dominantly central sleep apnea.
Me thods
Study Design and Oversight
The SERVE-HF trial was an international, multi-
center, randomized, parallel-group, event-driven 
study. Information about the study design has 
been reported previously.13 The trial was spon-
sored by ResMed. The study protocol, which is 
available with the full text of this article at 
NEJM.org, was designed by the steering commit-
tee with the support of the scientific advisory 
board and was approved by the ethics committee 
at each study center. The trial was conducted in 
accordance with Good Clinical Practice guide-
lines and the principles of the 2002 Declaration 
of Helsinki.
The steering committee oversaw the conduct 
of the trial and data analysis in collaboration 
with the sponsor according to a prespecified 
statistical analysis plan. The trial was reviewed 
by an independent data and safety monitoring 
committee. The first draft of the manuscript was 
prepared by the first three authors and the last 
author, who had unrestricted access to the data, 
with the assistance of an independent medical 
writer funded by the sponsor. The manuscript 
was reviewed and edited by all the authors. All 
the authors made the decision to submit the 
manuscript for publication and assume respon-
sibility for the accuracy and completeness of the 
analyses and for the fidelity of this report to the 
trial protocol.
Study Patients
Patients were eligible for participation in the 
study if they were 22 years of age or older and 
had symptomatic chronic heart failure and re-
duced ejection fraction. Specific requirements 
included a left ventricular ejection fraction of 
45% or less, New York Heart Association (NYHA) 
class III or IV heart failure or NYHA class II 
heart failure with at least one heart failure– 
related hospitalization within the 24 months be-
fore randomization, and stable, guideline-based 
medical treatment. Eligible participants also had 
predominantly central sleep apnea (AHI, ≥15 
events per hour, with >50% central events [apnea 
or hypopnea] and a central AHI of ≥10 events 
per hour). Full details of the inclusion and exclu-
sion criteria are provided in the Supplementary 
Appendix, available at NEJM.org. All the partici-
pants provided written informed consent.
Intervention
Adjustment of adaptive servo-ventilation was 
performed in the hospital with the use of poly-
somnographic or polygraphic monitoring. De-
fault settings were used (expiratory positive air-
The New England Journal of Medicine 
Downloaded from nejm.org at IMPERIAL COLLEGE LONDON on February 18, 2016. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
n engl j med 373;12 nejm.org September 17, 2015 1097
Adaptive Servo-Ventilation for Sleep Apnea in Heart Failure
way pressure, 5 cm of water; minimum pressure 
support, 3 cm of water; and maximum pressure 
support, 10 cm of water). The expiratory positive 
airway pressure was increased manually to con-
trol obstructive sleep apnea, and the maximum 
pressure support was increased to control central 
sleep apnea. A full face mask was recommended 
for the initiation of adaptive servo-ventilation.
Patients were advised to use the adaptive 
servo-ventilation device for at least 5 hours per 
night, 7 days per week. Adherence to therapy 
was defined as the use of adaptive servo-ventila-
tion for an average of at least 3 hours per night. 
The target was to reduce the AHI to less than 10 
events per hour within 14 days after starting 
adaptive servo-ventilation.
Follow-up
Clinic visits took place at study entry, after 
2 weeks, at 3 and 12 months, and every 12 months 
thereafter until the end of the study. Patients 
were contacted by telephone at 6 months and 
then at 12-month intervals. Patients in the adap-
tive servo-ventilation group also underwent 
polygraphy or polysomnography at each visit, 
and data were downloaded from the adaptive 
servo-ventilation device. Continual on-site moni-
toring was performed, with source-data verifi-
cation of core data in all the patients. Central 
monitoring of documents (patients’ records and 
case-report forms) regarding serious adverse 
events was performed before the assessments 
by the end-point review committee. After the 
protocol-specified goal of 651 identified and ad-
judicated primary end points was met, the trial 
was terminated, and final visits were arranged 
for all the patients so that end-of-trial assess-
ments could be performed and data regarding 
any remaining end points or adverse events could 
be collected before the database was locked.
End Points
The primary study end point in the time-to-event 
analysis was the first event of the composite of 
death from any cause, a lifesaving cardiovascu-
lar intervention, or an unplanned hospitalization 
for worsening chronic heart failure, with the 
latter two end-point events being assessed by the 
end-point review committee. Lifesaving cardio-
vascular intervention included cardiac transplan-
tation, implantation of a long-term ventricular 
assist device, resuscitation after sudden cardiac 
arrest, or appropriate shock for ventricular ar-
rhythmia in patients with an implantable cardio-
verter–defibrillator.
Subsequent hierarchical end points to be 
tested if the null hypothesis for the primary 
end point was rejected were the first secondary 
end point (which was the same as the primary end 
point but included cardiovascular death instead 
of death from any cause) and the second second-
ary end point (which was the same as the pri-
mary end point but included unplanned hospi-
talization for any cause instead of unplanned 
hospitalization related to heart failure) (see the 
Supplementary Appendix). Additional secondary 
end points were the time to death from any 
cause, the time to death from cardiovascular 
causes, and change in NYHA class and change 
in the 6-minute walk distance (both as assessed 
at follow-up visits).
Quality of life was assessed with the use of 
three instruments. Changes in general quality of 
life were measured with the use of the EuroQol 
Group 5-Dimension Self-Report Questionnaire 
(EQ-5D). Changes in disease-specific quality of 
life were measured with the use of the Minne-
sota Living with Heart Failure questionnaire. 
The effect of sleep apnea on daytime sleepiness 
was measured with the use of the Epworth Sleep-
iness Scale (on which scores range from 0 to 24, 
with higher scores indicating more daytime 
sleepiness).
Statistical Analysis
The study was designed to show a 20% reduction 
in the rate of the first primary end-point event 
with adaptive servo-ventilation. We calculated 
that data on 651 events had to be collected for 
the study to have a power of 80% to show that 
reduction, at an overall two-sided type I error 
rate of 5%. Because recruitment was slower than 
scheduled and the pooled event rate was below 
the expected rate in two blinded interim analy-
ses, the required sample size was adapted twice, 
with a planned total of 1193 patients to be re-
cruited over a period of 60 months, plus an ad-
ditional 2 years of follow-up. Recruitment con-
tinued for longer than planned owing to a delay 
with an associated substudy, which resulted in 
the recruitment of more than 1193 patients. The 
target number of 651 observed events was never 
changed.
The primary analysis was conducted in the 
intention-to-treat population, which consisted of 
all the patients who underwent randomization, 
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with adjudication of all the events that occurred 
before the database was locked. The analysis fol-
lowed a group-sequential design with two in-
terim analyses with O’Brien–Fleming stopping 
boundaries and two-sided log-rank tests com-
paring the control group with the adaptive ser-
vo-ventilation group. The significance level of 
the final analysis step was 0.0430, and the cor-
responding rejection boundary of the standard-
ized log-rank statistic was ±2.024, keeping an 
overall two-sided significance level of 5%. The 
excess of events at the termination of the trial 
was included in the final analysis with the use 
of the inverse normal method (a combination 
rule for interim tests that does not require equal 
sample sizes of the interim intervals). Cause-
specific hazard ratios were calculated, and cu-
mulative incidence curves that can take potential 
competing risks into account were used to visu-
alize survival data. Further details regarding the 
statistical analysis, including analyses of the 
secondary end points and sensitivity analyses, 
are provided in the Supplementary Appendix.
R esult s
Study Patients
A total of 1325 patients were enrolled from Feb-
ruary 2008 through May 2013 at 91 centers and 
were included in the intention-to-treat analysis; 
659 patients were assigned to the control group 
and 666 to the adaptive servo-ventilation group 
(Fig. 1). Information regarding patient with-
drawals, follow-up, and the handling of missing 
data is provided in the Supplementary Appendix. 
Table 1 provides details regarding the demo-
graphic and clinical characteristics of the pa-
tients in the two study groups at baseline; the 
countries of enrollment are listed in Table S1 in 
the Supplementary Appendix. There were no 
significant differences in baseline characteris-
tics between the control group and the adaptive 
servo-ventilation group, except for the rate of 
antiarrhythmic drug use, which was higher in 
the adaptive servo-ventilation group than in the 
control group (P = 0.005) (Table 1). The respirato-
ry characteristics at baseline are shown in Table 2.
Study Intervention and Follow-up
The median duration of follow-up was 31 months 
(range, 0 to 80). We assessed the median posi-
tive airway pressure values at each time point 
and then calculated the mean of the median 
values (i.e., mean median values). In the adaptive 
servo-ventilation group, the device-measured 
mean median values of expiratory positive air-
way pressure were 5.5 cm of water (95% con-
fidence interval [CI], 5.4 to 5.6) at baseline and 
5.7 cm of water (95% CI, 5.6 to 5.8) at 12 months; 
the device-measured mean median values of in-
spiratory positive airway pressure were 9.7 cm of 
water (95% CI, 9.6 to 9.8) at baseline and 9.8 cm 
of water (95% CI, 9.6 to 9.9) at 12 months. Ta-
ble S2 in the Supplementary Appendix lists ad-
ditional device-measured data.
A total of 60% of the patients in the adap-
tive servo-ventilation group used adaptive servo-
ventilation for an average of 3 hours per night or 
more during the trial period (Table S3 in the Sup-
plementary Appendix). Sleep-disordered breath-
ing was well controlled during adaptive servo-
ventilation therapy. At 12 months, the mean 
AHI was 6.6 events per hour, and the oxygen 
desaturation index (the number of times per 
hour of recording that the blood oxygen level 
drops by ≥3 percentage points from baseline) 
was 8.6 events per hour (Table S4 in the Supple-
mentary Appendix).
Survival and Cardiovascular End Points
A summary of end-point events according to 
treatment group is provided in Table 3. The inci-
dence of the primary end point did not differ 
significantly between the adaptive servo-ventila-
tion group and the control group, with event rates 
of 54.1% and 50.8%, respectively (hazard ratio, 
1.13; 95% CI, 0.97 to 1.31; P = 0.10) (Fig. 2A). 
Because the first and second secondary end 
points were prespecified to be analyzed hierar-
chically only if the null hypothesis for the pri-
mary end point was rejected, the results of those 
analyses are considered to be exploratory. How-
ever, there was no significant difference be-
tween the two groups with respect to either of 
these end points.
All-cause mortality and cardiovascular mor-
tality were higher in the adaptive servo-ventila-
tion group than in the control group. All-cause 
mortality was 34.8% and 29.3%, respectively 
(hazard ratio for death from any cause, 1.28; 
95% CI, 1.06 to 1.55; P = 0.01), and cardiovascu-
lar mortality was 29.9% and 24.0%, respectively 
(hazard ratio for death from cardiovascular 
causes, 1.34; 95% CI, 1.09 to 1.65; P = 0.006) 
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(Fig. 2B and 2C). Similar findings were noted in 
the sensitivity analyses of all-cause mortality 
and cardiovascular mortality (Tables S5 and S6 
and Fig. S1 in the Supplementary Appendix).
Subgroup Analyses
Subgroup analyses were conducted for the pri-
mary end point and for cardiovascular mortality. 
In the analysis of the primary end point, there 
was a significant modification of effect by the 
degree of Cheyne–Stokes respiration, and in the 
analysis of cardiovascular mortality, there was a 
significant modification of effect by the left 
ventricular ejection fraction (Fig. S2 in the Sup-
plementary Appendix).
Symptoms and Quality of Life
Assessments performed with the use of the Min-
nesota Living with Heart Failure questionnaire, 
the EQ-5D, and the NYHA classification showed 
no significant differences between the adaptive 
servo-ventilation group and the control group 
during the study (Figs. S3, S4, and S5 in the 
Supplementary Appendix). Although the Epworth 
Sleepiness Scale score decreased in the two study 
groups, the change was significantly greater in 
the adaptive servo-ventilation group (P<0.001) 
(Fig. S6 in the Supplementary Appendix). There 
was a gradual decline in the 6-minute walk dis-
tance in both the control group and the adaptive 
servo-ventilation group, but the decline was 
Figure 1. Randomization, Treatment, and Follow-up of the Patients.
Patients who withdrew consent did so for both study participation and follow­up (see the Supplementary Appendix). 
Of the 73 patients who withdrew consent in the control group, 3 had started adaptive servo­ventilation (ASV), and 
of the 82 who withdrew consent in the ASV group, 2 had discontinued ASV. CPAP denotes continuous positive air­
way pressure, and PAP positive airway pressure.
1325 Were included in the
intention-to-treat analysis
1325 Patients underwent randomization
659 Were assigned to receive control
therapy
655 Received control therapy
4 Did not receive control therapy
owing to starting ASV
666 Were assigned to receive ASV
645 Received ASV
21 Did not receive ASV
73 Withdrew consent
19 Had primary end-point
event before consent
was withdrawn
54 Had no primary end-
point event before
consent was withdrawn
3 Started ASV
before consent was
withdrawn
8 Were lost to follow-up
2 Started ASV before
being lost to follow-up
82 Withdrew consent
19 Had primary end-point
event before consent
was withdrawn
63 Had no primary end-
point event before
consent was withdrawn
2 Discontinued ASV
before consent was
withdrawn
1 Was lost to follow-up
578 Completed the study
98 Started PAP therapy
87 Received ASV
8 Received CPAP
2 Received bilevel PAP
1 Received unspecified therapy
583 Completed the study
168 Discontinued ASV
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significantly more pronounced in the adaptive 
servo-ventilation group (P = 0.02) (Fig. S7 in the 
Supplementary Appendix).
Discussion
The SERVE-HF study showed that although 
adaptive servo-ventilation therapy effectively 
treated central sleep apnea, it did not have a 
significant effect on the composite end point of 
death from any cause, lifesaving cardiovascular 
intervention, or unplanned hospitalization for 
worsening heart failure. There was no beneficial 
effect of adaptive servo-ventilation on a broad 
spectrum of functional measures, including 
quality-of-life measures, 6-minute walk distance, 
or symptoms. In fact, there was a significant 
increase in both cardiovascular mortality and 
Characteristic
Control 
(N = 659)
Adaptive Servo-Ventilation 
(N = 666)
Age — yr 69.3±10.4 69.6±9.5
Male sex — no. (%) 599 (90.9) 599 (89.9)
Body weight — kg 86.1±17.5 85.6±15.8
Body­mass index† 28.6±5.1 28.4±4.7
NYHA class — no./total no. (%)
II 194/654 (29.7) 195/662 (29.5)
III 454/654 (69.4) 456/662 (68.9)
IV 6/654 (0.9) 11/662 (1.7)
Left ventricular ejection fraction — %‡
Mean 32.5±8.0 32.2±7.9
Range 9.0–71.0 10.0–54.0
Diabetes mellitus — no./total no. (%) 252/653 (38.6) 254/660 (38.5)
Cause of heart failure — no./total no. (%)
Ischemic 366/642 (57.0) 390/653 (59.7)
Nonischemic 276/642 (43.0) 263/653 (40.3)
Blood pressure — mm Hg
Systolic 122.1±19.6 122.3±19.0
Diastolic 73.3±11.5 73.7±11.3
Electrocardiographic finding — no./total no. (%)
Left bundle­branch block§ 65/295 (22.0) 79/304 (26.0)
Sinus rhythm 395/646 (61.1) 372/650 (57.2)
Atrial fibrillation 147/646 (22.8) 178/650 (27.4)
Other 104/646 (16.1) 100/650 (15.4)
Implanted device — no. (%) 364 (55.2) 362 (54.4)
No device 295 (44.8) 304 (45.6)
Non­CRT pacemaker 29 (4.4) 32 (4.8)
ICD 161 (24.4) 163 (24.5)
CRT­P 21 (3.2) 14 (2.1)
CRT­D 153 (23.2) 153 (23.0)
Hemoglobin — g/dl 13.9±1.5 13.8±1.6
Creatinine — mg/dl¶ 1.4±0.6 1.4±0.6
Estimated GFR — ml/min/1.73 m2 59.3±20.8 57.8±21.1
6­Min walk distance — m 337.9±127.5 334.0±126.4
Table 1. Demographic and Clinical Characteristics of the Patients at Baseline.*
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Characteristic
Control 
(N = 659)
Adaptive Servo-Ventilation 
(N = 666)
Concomitant cardiac medication — no./total no. (%)
ACE inhibitor or ARB 603/659 (91.5) 613/666 (92.0)
Beta­blocker 611/659 (92.7) 612/666 (91.9)
Aldosterone antagonist 325/659 (49.3) 316/666 (47.4)
Diuretic 561/659 (85.1) 561/666 (84.2)
Cardiac glycoside 124/657 (18.9) 149/666 (22.4)
Antiarrhythmic drug 89/659 (13.5) 128/666 (19.2)
*  Plus–minus values are means ±SD. There were no significant differences between the control group and the adaptive 
servo­ventilation group, except for the rate of antiarrhythmic drug use, which was higher in the adaptive servo­ventila­
tion group than in the control group (P = 0.005). Data were missing for the following characteristics: body weight, for  
8 patients in the control group and 9 in the adaptive servo­ventilation group; body­mass index, for 8 and 9, respectively; 
left ventricular ejection fraction, for 126 and 130, respectively; systolic blood pressure, for 15 and 11, respectively; dia­
stolic blood pressure, for 15 and 12, respectively; hemoglobin, for 27 and 25, respectively; creatinine level, for 30 and 
29, respectively; and 6­minute walk distance, for 41 and 34, respectively. ACE denotes angiotensin­converting–enzyme, 
ARB angiotensin­receptor blocker, CRT cardiac­resynchronization therapy, CRT­D CRT with defibrillator function, CRT­P 
CRT with pacemaker function, GFR glomerular filtration rate, ICD implantable cardioverter–defibrillator, and NYHA 
New York Heart Association.
†  The body­mass index is the weight in kilograms divided by the square of the height in meters.
‡  The measurement of left ventricular ejection fraction was added to the study protocol 32 months after the first patient 
underwent randomization.
§  Left bundle­branch block was assessed in patients who did not have an implanted device.
¶  To convert the values for creatinine to micromoles per liter, multiply by 88.4.
Table 1. (Continued.)
Characteristic
Control 
(N = 659)
Adaptive Servo-Ventilation 
(N = 666)
Epworth Sleepiness Scale score† 7.1±4.6 7.0±4.3
AHI — no. of events/hr 31.7±13.2 31.2±12.7
Central apnea index/total AHI — % 46.5±30.0 44.6±28.9
Central AHI/total AHI — % 81.8±15.7 80.8±15.5
Oxygen desaturation index — no. of events/hr‡ 32.8±19.0 32.1±17.7
Oxygen saturation — %
Mean 92.8±2.5 92.8±2.3
Minimum 80.3±7.5 80.7±7.0
Time with oxygen saturation <90% — min 55.7±73.9 50.5±68.2
*  Plus–minus values are means ±SD. There were no significant differences between the control group and the adaptive 
servo­ventilation group. Data were missing for the following characteristics: Epworth Sleepiness Scale score, for 8 pa­
tients in the control group and 13 in the adaptive servo­ventilation group; the apnea–hypopnea index (AHI; the number 
of occurrences of apnea or hypopnea per hour), for 1 in the adaptive servo­ventilation group; central apnea index divid­
ed by the total AHI, for 2 in the adaptive servo­ventilation group; central AHI divided by the total AHI, for 1 in the adap­
tive servo­ventilation group; mean oxygen desaturation index, for 4 in the control group and 7 in the adaptive servo­
ventilation group; average oxygen saturation, for 3 in the adaptive servo­ventilation group; minimum oxygen saturation, 
for 5 in the adaptive servo­ventilation group; and time with an oxygen saturation of less than 90%, for 3 in the control 
group and 10 in the adaptive servo­ventilation group.
†  Scores on the Epworth Sleepiness Scale range from 0 to 24, with higher scores indicating more daytime sleepiness.
‡  The oxygen desaturation index is the number of times per hour of recording that the blood oxygen level drops by ≥3 
percentage points from baseline.
Table 2. Respiratory Characteristics at Baseline.*
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all-cause mortality in the adaptive servo-ventila-
tion group. The signal for the primary end point 
was stronger in patients with a higher propor-
tion of Cheyne–Stokes respiration than in those 
who had a lower proportion, and the signal for 
cardiovascular death was stronger in patients 
with very low left ventricular ejection fraction 
than in those with a higher left ventricular ejec-
tion fraction.
The findings of this study contrast with evi-
dence from smaller studies and meta-analyses 
that have shown improvements in surrogate 
markers, including the plasma concentration of 
brain natriuretic peptide (BNP), left ventricular 
ejection fraction, quality-of-life scores, functional 
outcomes, and mortality among patients who 
have heart failure with reduced ejection fraction 
and have central sleep apnea that is treated with 
adaptive servo-ventilation.11,14-17 The recently pub-
lished results of the Study of the Effects of Adap-
tive Servo-ventilation Therapy on Cardiac Func-
tion and Remodeling in Patients with Chronic 
Event
Control 
(N = 659)
Adaptive Servo-Ventilation 
(N = 666)
Hazard Ratio 
(95% CI) P Value
No. of 
Patients (%)
No. of Events/Yr 
(95% CI)
No. of 
Patients (%)
No. of Events/Yr 
(95% CI)
Primary end point† 335 (50.8) 0.212 
(0.190−0.236)
360 (54.1) 0.245 
(0.220−0.272)
1.13 
(0.97−1.31)
0.10
First secondary end point† 317 (48.1) 0.200 
(0.179−0.224)
345 (51.8) 0.235 
(0.211−0.261)
1.15 
(0.98−1.34)
0.08
Second secondary end point† 465 (70.6) 0.405 
(0.369−0.444)
482 (72.4) 0.441 
(0.403−0.483)
1.07 
(0.94−1.22)
0.28
Death from any cause 193 (29.3) 0.093 
(0.081−0.107)
232 (34.8) 0.119 
(0.104−0.135)
1.28 
(1.06−1.55)
0.01
Cardiovascular death 158 (24.0) 0.076 
(0.065−0.089)
199 (29.9) 0.102 
(0.088−0.117)
1.34 
(1.09−1.65)
0.006
Hospitalization for any cause 448 (68.0) 0.384 
(0.349−0.421)
452 (67.9) 0.411 
(0.374−0.451)
1.05 
(0.92−1.20)
0.47
Unplanned hospitalization for 
worsening heart failure
272 (41.3) 0.164 
(0.145−0.185)
287 (43.1) 0.190 
(0.169−0.214)
1.13 
(0.95−1.33)
0.16
Heart transplantation 12 (1.8) 0.006 
(0.003−0.010)
8 (1.2) 0.004 
(0.002−0.008)
0.70 
(0.28−1.70)
0.43
Implantation of long­term VAD 10 (1.5) 0.005 
(0.002−0.009)
16 (2.4) 0.008 
(0.005−0.013)
1.67 
(0.76−3.68)
0.20
Resuscitation 19 (2.9) 0.009 
(0.006−0.014)
25 (3.8) 0.013 
(0.008−0.019)
1.40 
(0.77−2.54)
0.27
Resuscitation for cardiac 
arrest
16 (2.4) 0.008 
(0.004−0.013)
18 (2.7) 0.009 
(0.005−0.015)
1.19 
(0.61−2.34)
0.61
Appropriate shock 65 (9.9) 0.033 
(0.026−0.043)
45 (6.8) 0.024 
(0.017−0.032)
0.71 
(0.48−1.04)
0.08
Noncardiovascular death 35 (5.3) 0.017 
(0.012−0.024)
33 (5.0) 0.017 
(0.012−0.024)
1.00 
(0.62−1.62)
0.99
*  VAD denotes ventricular assist device.
†  The primary study end point in the time­to­event analysis was the first event of death from any cause, lifesaving cardiovascular intervention 
(cardiac transplantation, implantation of a long­term ventricular assist device, resuscitation after sudden cardiac arrest, or appropriate shock 
for ventricular arrhythmia in patients with an ICD), and unplanned hospitalization for worsening chronic heart failure. The first secondary 
end point was the same as the primary end point, but with cardiovascular death instead of death from any cause. The second secondary 
end point was the same as the primary end point, but with unplanned hospitalization for any cause instead of unplanned hospitalization 
 related to heart failure.
Table 3. Incidence of End-Point Events.*
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Heart Failure (SAVIOR-C) showed a lack of effect 
of adaptive servo-ventilation therapy on left ven-
tricular ejection fraction and plasma BNP con-
centrations up to a maximum of 24 weeks.18 
However, improvements in quality of life and 
clinical status were associated with adaptive 
servo-ventilation therapy in that trial — findings 
that were not confirmed by our study.
The CANPAP trial was a large, randomized, 
outcome study that investigated CPAP treatment 
for central sleep apnea in patients with heart 
failure.9 That trial showed no benefit of CPAP. 
A post hoc analysis of data from that trial indi-
cated that mortality might be lower when CPAP 
therapy is associated with an early and signifi-
cant reduction in AHI (to <15 events per hour at 
3 months).10 However, in our trial, adaptive ser-
vo-ventilation showed no benefit with respect to 
cardiovascular end points, despite effective con-
trol of sleep-disordered breathing.
The early and sustained increase in cardiovas-
cular mortality seen in the adaptive servo-venti-
lation group in this trial was unexpected, and the 
pathophysiological features of this effect remain 
to be elucidated. One possible explanation is 
that central sleep apnea may be a compensatory 
mechanism in patients with heart failure, as has 
been suggested previously.19 Potentially beneficial 
consequences of central sleep apnea, particularly 
Cheyne–Stokes respiration, in patients with heart 
failure that could have been attenuated by adap-
tive servo-ventilation include the resting of re-
spiratory muscles, attenuation of excessive sym-
pathetic nervous system activity, avoidance of 
hypercapnic acidosis, hyperventilation-related in-
creases in end-expiratory lung volume, and intrin-
sic positive airway pressure.19 Diminishing this 
compensatory adaptive respiratory pattern with 
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Figure 2. Cumulative Incidence Curves for the Primary 
End Point, Death from Any Cause, and Cardiovascular 
Death.
The primary end point was a composite of death from 
any cause, lifesaving cardiovascular intervention (cardiac 
transplantation, implantation of a long­term ventricular 
assist device, resuscitation after sudden cardiac arrest, 
or appropriate shock for ventricular arrhythmia in pa­
tients with an implantable cardioverter–defibrillator), 
and unplanned hospitalization for worsening chronic 
heart failure.
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adaptive servo-ventilation may be detrimental in 
patients with heart failure, as suggested by the 
subgroup analysis that showed a positive asso-
ciation between the proportion of Cheyne–Stokes 
respiration and the adverse effect of adaptive 
servo-ventilation on cardiovascular mortality.
Another possible explanation is that the ap-
plication of positive airway pressure may impair 
cardiac function in at least some patients with 
heart failure. A number of studies have docu-
mented decreased cardiac output and stroke vol-
ume during positive airway pressure therapy, 
particularly when the pulmonary-capillary wedge 
pressure is low.20-23 However, the hemodynamic 
effects of positive airway pressure appear to be 
neutral or beneficial in patients with heart failure 
and high wedge pressures.20-22,24 Even in patients 
with severe systolic dysfunction (left ventricular 
ejection fraction, ≤35%), short-term treatment 
with bilevel positive airway pressure therapy has 
been shown to significantly improve left ven-
tricular performance.25 Furthermore, no safety 
concerns have been identified during the short-
term application of positive airway pressure in 
patients with decompensated heart failure.26
Our study has a few limitations. The main 
limitation of the study was its unblinded design, 
which has the potential to introduce bias. How-
ever, this bias would be more likely to favor the 
active treatment group, particularly with regard 
to quality of life, and improvement in this out-
come was not seen in the study results. In addi-
tion, owing to the epidemiologic factors associ-
ated with central sleep apnea and with heart 
failure with reduced ejection fraction, relatively 
few women were recruited to the study. Finally, 
the study was conducted in patients who had 
heart failure with reduced ejection fraction, and 
therefore the results cannot be generalized to 
patients who have heart failure with preserved 
ejection fraction. The study results also cannot be 
extrapolated to patients with predominantly ob-
structive sleep apnea. As compared with central 
apnea events, obstructive apnea events may lead 
to more adverse loading of the heart by increasing 
the left ventricular afterload by means of the com-
bined effects of elevations in systemic blood pres-
sure and the generation of increased negative 
intrathoracic pressure, which can be reversed by 
means of positive airway pressure therapies.
It should be noted that the algorithms used 
by different adaptive servo-ventilation devices vary, 
but the principle of treatment is the same (i.e., 
back-up rate ventilation with adaptive pressure 
support). Although previous studies have not dif-
ferentiated between devices in terms of the effects 
of adaptive servo-ventilation therapy, there is an 
ongoing study of this question (ClinicalTrials.gov 
number, NCT01128816) that may help deter-
mine whether the safety signal identified in 
SERVE-HF is limited to a particular device or 
algorithm.
In conclusion, we found that in patients who 
had heart failure with a reduced ejection fraction 
and predominantly central sleep apnea, the ad-
dition of adaptive servo-ventilation to guideline-
based medical treatment did not improve the 
outcome. The risk of cardiovascular death was 
increased by 34%, which was sustained through-
out the trial, and there was no beneficial effect 
on quality of life or symptoms of heart failure. 
These results were seen despite effective control 
of central sleep apnea during adaptive servo-
ventilation therapy.
The views expressed in this article are those of the authors 
and do not necessarily represent the official views of the Na-
tional Institutes of Health.
Supported by ResMed and by grants from the National Insti-
tute for Health Research (NIHR) Cardiovascular Biomedical 
Research Unit (to Dr. Cowie), the NIHR Respiratory Biomedical 
Research Unit (to Dr. Simonds), and the National Institutes of 
Health (R01HL065176, to Dr Somers).
Dr. Cowie reports receiving consulting fees from Servier, 
Novartis, Pfizer, St. Jude Medical, Boston Scientific, Respicar-
dia, and Medtronic and grant support through his institution 
from Bayer; Dr. Woehrle, being an employee of ResMed; Dr. 
Wegscheider, receiving grant support from ResMed; Dr. Anger-
mann, receiving fees for serving on advisory boards from 
ResMed, Servier, Boehringer Ingelheim, and Vifor Pharma, fees 
for serving on a steering committee from ResMed, lecture fees 
from Servier and Vifor Pharma, grant support from ResMed, 
Thermo Fisher Scientific, Boehringer Ingelheim, Lundbeck, and 
Vifor Pharma, financial support for statistical analyses from 
Thermo Fisher Scientific, and study medication from Lundbeck; 
Dr. d’Ortho, receiving fees for serving on advisory boards from 
ResMed and IP Santé, lecture fees from ResMed, Philips, IP 
Santé, and VitalAire, grant support from Fisher and Paykel 
Healthcare, ResMed, Philips, ADEP Assistance, and IP Santé, 
and small material donations from VitalAire; Dr. Somers, re-
ceiving consulting fees from PricewaterhouseCoopers, Sorin, 
GlaxoSmithKline, Respicardia, uHealth, Ronda Grey, and 
ResMed, working with Mayo Medical Ventures on intellectual 
property related to sleep and cardiovascular disease, and having 
a pending patent (12/680073) related to biomarkers of sleep ap-
nea; Dr. Zannad, receiving fees for serving on steering commit-
tees from Janssen Pharmaceutica, Bayer, Pfizer, Novartis, Bos-
ton Scientific, ResMed, and Takeda Pharmaceutical, receiving 
consulting fees from Servier, Stealth Peptides, Amgen, and 
CVRx, and receiving lecture fees from Mitsubishi; and Dr. Tes-
chler, receiving consulting fees, grant support, and hardware 
and software for the development of devices from ResMed. No 
other potential conflict of interest relevant to this article was 
reported.
The New England Journal of Medicine 
Downloaded from nejm.org at IMPERIAL COLLEGE LONDON on February 18, 2016. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
n engl j med 373;12 nejm.org September 17, 2015 1105
Adaptive Servo-Ventilation for Sleep Apnea in Heart Failure
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
We thank the team from the Clinical Research Institute, Mu-
nich, Germany, for overseeing the trial; Nicola Ryan, B.Sc., inde-
pendent medical writer, for medical writing support; and Anika 
Buchholz, Ph.D., Christine Eulenburg, Ph.D., Anna Suling, 
Ph.D., Susanne Lezius, M.Sc., and Eik Vettorazzi, M.Sc., of the 
Department of Medical Biometry and Epidemiology, University 
Medical Center Eppendorf, Hamburg, Germany, for statistical 
calculations.
References
1. Oldenburg O, Lamp B, Faber L, Tesch-
ler H, Horstkotte D, Töpfer V. Sleep-disor-
dered breathing in patients with symptom-
atic heart failure: a contemporary study of 
prevalence in and characteristics of 700 
patients. Eur J Heart Fail 2007; 9: 251-7.
2. Lévy P, Pépin J-L, Tamisier R, Neuder 
Y, Baguet J-P, Javaheri S. Prevalence and 
impact of central sleep apnea in heart fail-
ure. Sleep Med Clin 2007; 2: 615-21.
3. Oldenburg O, Bitter T, Wiemer M, 
Langer C, Horstkotte D, Piper C. Pulmo-
nary capillary wedge pressure and pulmo-
nary arterial pressure in heart failure pa-
tients with sleep-disordered breathing. 
Sleep Med 2009; 10: 726-30.
4. Bitter T, Westerheide N, Prinz C, et al. 
Cheyne-Stokes respiration and obstructive 
sleep apnoea are independent risk factors 
for malignant ventricular arrhythmias re-
quiring appropriate cardioverter-defibril-
lator therapies in patients with congestive 
heart failure. Eur Heart J 2011; 32: 61-74.
5. Kasai T, Floras JS, Bradley TD. Sleep 
apnea and cardiovascular disease: a bidi-
rectional relationship. Circulation 2012; 
126: 1495-510.
6. Somers VK, White DP, Amin R, et al. 
Sleep apnea and cardiovascular disease: 
an American Heart Association/American 
College of Cardiology Foundation Scien-
tific Statement from the American Heart 
Association Council for High Blood Pres-
sure Research Professional Education Com-
mittee, Council on Clinical Cardiology, 
Stroke Council, and Council on Cardio-
vascular Nursing. J Am Coll Cardiol 2008; 
52: 686-717.
7. Javaheri S, Shukla R, Zeigler H, Wex-
ler L. Central sleep apnea, right ventricu-
lar dysfunction, and low diastolic blood 
pressure are predictors of mortality in 
systolic heart failure. J Am Coll Cardiol 
2007; 49: 2028-34.
8. Yumino D, Wang H, Floras JS, et al. 
Relationship between sleep apnoea and 
mortality in patients with ischaemic heart 
failure. Heart 2009; 95: 819-24.
9. Bradley TD, Logan AG, Kimoff RJ, et al. 
Continuous positive airway pressure for 
central sleep apnea and heart failure. 
N Engl J Med 2005; 353: 2025-33.
10. Arzt M, Floras JS, Logan AG, et al. 
Suppression of central sleep apnea by con-
tinuous positive airway pressure and trans-
plant-free survival in heart failure: a post 
hoc analysis of the Canadian Continuous 
Positive Airway Pressure for Patients with 
Central Sleep Apnea and Heart Failure Trial 
(CANPAP). Circulation 2007; 115: 3173-80.
11. Sharma BK, Bakker JP, McSharry DG, 
Desai AS, Javaheri S, Malhotra A. Adaptive 
servoventilation for treatment of sleep-
disordered breathing in heart failure: 
a systematic review and meta-analysis. 
Chest 2012; 142: 1211-21.
12. Teschler H, Döhring J, Wang YM, 
Berthon-Jones M. Adaptive pressure sup-
port servo-ventilation: a novel treatment 
for Cheyne-Stokes respiration in heart 
failure. Am J Respir Crit Care Med 2001; 
164: 614-9.
13. Cowie MR, Woehrle H, Wegscheider 
K, et al. Rationale and design of the 
SERVE-HF study: treatment of sleep-dis-
ordered breathing with predominant cen-
tral sleep apnoea with adaptive servo-
ventilation in patients with chronic heart 
failure. Eur J Heart Fail 2013; 15: 937-43.
14. Hastings PC, Vazir A, Meadows GE, et 
al. Adaptive servo-ventilation in heart 
failure patients with sleep apnea: a real 
world study. Int J Cardiol 2010; 139: 17-24.
15. Nakamura S, Asai K, Kubota Y, et al. 
Impact of sleep-disordered breathing and 
efficacy of positive airway pressure on mor-
tality in patients with chronic heart fail-
ure and sleep-disordered breathing: a meta-
analysis. Clin Res Cardiol 2015; 104: 208-16.
16. Oldenburg O, Schmidt A, Lamp B, et 
al. Adaptive servoventilation improves 
cardiac function in patients with chronic 
heart failure and Cheyne-Stokes respira-
tion. Eur J Heart Fail 2008; 10: 581-6.
17. Takama N, Kurabayashi M. Effect of 
adaptive servo-ventilation on 1-year prog-
nosis in heart failure patients. Circ J 2012; 
76: 661-7.
18. Momomura S, Seino Y, Kihara Y, et al. 
Adaptive servo-ventilation therapy for pa-
tients with chronic heart failure in a con-
firmatory, multicenter, randomized, con-
trolled study. Circ J 2015; 79: 981-90.
19. Naughton MT. Cheyne-Stokes respira-
tion: friend or foe? Thorax 2012; 67: 357-
60.
20. Bradley TD, Holloway RM, McLaugh-
lin PR, Ross BL, Walters J, Liu PP. Cardiac 
output response to continuous positive 
airway pressure in congestive heart fail-
ure. Am Rev Respir Dis 1992; 145: 377-82.
21. De Hoyos A, Liu PP, Benard DC, Brad-
ley TD. Haemodynamic effects of contin-
uous positive airway pressure in humans 
with normal and impaired left ventricular 
function. Clin Sci (Lond) 1995; 88: 173-8.
22. Grace MP, Greenbaum DM. Cardiac 
performance in response to PEEP in pa-
tients with cardiac dysfunction. Crit Care 
Med 1982; 10: 358-60.
23. Philip-Joët FF, Paganelli FF, Dutau 
HL, Saadjian AY. Hemodynamic effects of 
bilevel nasal positive airway pressure ven-
tilation in patients with heart failure. 
Respiration 1999; 66: 136-43.
24. Lenique F, Habis M, Lofaso F, Dubois-
Randé JL, Harf A, Brochard L. Ventilatory 
and hemodynamic effects of continuous 
positive airway pressure in left heart fail-
ure. Am J Respir Crit Care Med 1997; 155: 
500-5.
25. Acosta B, DiBenedetto R, Rahimi A, 
et al. Hemodynamic effects of noninva-
sive bilevel positive airway pressure on 
patients with chronic congestive heart 
failure with systolic dysfunction. Chest 
2000; 118: 1004-9.
26. Gray AJ, Goodacre S, Newby DE, et al. 
A multicentre randomised controlled trial 
of the use of continuous positive airway 
pressure and non-invasive positive pres-
sure ventilation in the early treatment of 
patients presenting to the emergency de-
partment with severe acute cardiogenic 
pulmonary oedema: the 3CPO trial. 
Health Technol Assess 2009; 13: 1-106.
Copyright © 2015 Massachusetts Medical Society.
receive immediate notification when an article  
is published online first
To be notified by e-mail when Journal articles  
are published Online First, sign up at NEJM.org.
The New England Journal of Medicine 
Downloaded from nejm.org at IMPERIAL COLLEGE LONDON on February 18, 2016. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
